Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 11/20 | 0.70 |
| ▸ | NTSR2 | O95665 | 6/20 | 0.70 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.65 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.64 |
| ▸ | NPY1R | P25929 | 2/20 | 0.64 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.64 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.64 |
| ▸ | NPY2R | P49146 | 1/20 | 0.61 |
| ▸ | NPY4R | P50391 | 1/20 | 0.61 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Neurotensin SCHEMBL29357707 | 0.98 | NTSR1 (0.70) | NTSR1NTSR2SORT1OPRD1OPRM1 | |
| Neurotensin SCHEMBL29851748 | 0.98 | NTSR1 (0.70) | NTSR1NTSR2SORT1OPRD1OPRM1 | |
| SCHEMBL30446151 | 0.93 | NMUR2 (0.67) | NTSR1NTSR2NPY1R | |
| Neurotensin SCHEMBL30483709 | 0.90 | KDM1A (0.61) | NTSR1NTSR2SORT1NPY1RNPY2R | |
| SCHEMBL30957024 | 0.90 | KDM1A (0.61) | NTSR1NTSR2SORT1NPY1RNPY2R | |
| SCHEMBL29402893 | 0.84 | HCRTR1 (0.68) | NTSR1OPRD1OPRM1OPRK1NPY1R | |
| SCHEMBL29361023 | 0.84 | NTSR1 (0.74) | NTSR1NTSR2SORT1OPRD1OPRM1 | |
| SCHEMBL29930119 | 0.84 | NTSR1 (0.87) | NTSR1NTSR2SORT1OPRD1OPRM1 | |
| SCHEMBL31302260 | 0.84 | KDM1A (0.58) | OPRD1NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL38650581 | 0.84 | KDM1A (0.62) | OPRM1OPRK1NPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078095-A1 | NEUROTENSIN RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-19 | — | — | US | disclosed |
| EP-3712131-B1 | NEUROTENSIN RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078095-A1 | NEUROTENSIN RECEPTOR LIGANDS | NTSR1, NTSR2, GRPR | NTSR1 1/4885NTSR2 2/4885SORT1 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.